Type 1 Diabetes Recurrence in Pancreas Transplants

Completed

Conditions studied: Diabetes Mellitus, Type 1

In brief

The hypothesis is that humoral and cellular islet-specific responses are an early risk factor for recurrence of autoimmunity and hyperglycemia in simultaneous pancreas-kidney (SPK) recipients independent of alloimmunity. This study will test the hypothesis and will assess their individual and combined predictive value.

Key facts

Study ID

NCT01047865

Run by

University of Miami

People needed

238

Starts

2005-05-01

Expected to finish

2026-01-05

Last updated by the study team

2026-05-29

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient has been fully informed and has signed a dated IRB approval informed consent form and is willing to follow study procedures for the extent of the study (24 months). Parent or legal guardian must provide written consent for patients <18 years of age.
• Age 18-75 years.
• Recipient of simultaneous pancreas and kidney transplant
• Primary or secondary renal allograft: living or deceased

You may not qualify if…

• Patient has previously received or is receiving an organ transplant other than a pancreas-kidney.

Where it is running

• University of Miami Miller School of Medicine Transplant Clinic — Miami, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.